OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
289
Results
Show all
Save search
Copy query
Show results for
Unknown
(281)
Transcriptomics
(5)
Proteomics
(3)
Organisms
Homo sapiens
(3)
Mus musculus
(2)
Trypanosoma brucei
(2)
Burkholderia ambifaria
(1)
Repository
biostudies-arrayexpress
(5)
pride
(3)
Tissue
Cell culture
(1)
Spleen
(1)
Stem cell
(1)
Disease
Trypanosomiasis
(2)
Adrenocortical Adenoma
(1)
Acute leukemia
(1)
Technology Type
Mass Spectrometry
(3)
Affinity purification coupled with mass spectrometry proteomics
(1)
Bottom-up proteomics
(1)
Data-dependent acquisition
(1)
Data-independent acquisition
(1)
Shotgun proteomics
(1)
Instrument Platform
Illumina HiSeq 2000
(1)
Publication Date
2011
(2)
2023
(2)
2014
(1)
2012
(1)
2009
(1)
2025
(1)
Study type
Transcription profiling by array
(3)
Methylation profiling by array
(1)
RNA-seq of coding RNA
(1)
Release Date
2022
(33)
2021
(26)
2024
(24)
2023
(22)
2020
(22)
2025
(21)
2018
(21)
2015
(20)
2019
(17)
2016
(14)
2017
(11)
2014
(10)
2012
(10)
2013
(9)
2011
(7)
2009
(6)
2010
(5)
2008
(4)
2026
(3)
2005
(1)
Lab affiliation
College of Science and Mathematics, Kennesaw State University, USA
(1)
Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
(1)
Kennesaw State University
(1)
Previous
page
1 / 29
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
29
Next
page
Sort
by:
Relevance
Page size
10
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
Not available
S-EPMC5140034
|
biostudies-literature
Cite
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Not available
S-EPMC8372245
|
biostudies-literature
Cite
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Not available
S-EPMC6107856
|
biostudies-literature
Cite
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Not available
S-EPMC10472096
|
biostudies-literature
Cite
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.
Not available
S-EPMC4141515
|
biostudies-literature
Cite
Structural insight into methyl-coenzyme M reductase chemistry using coenzyme B analogues .
Not available
S-EPMC3098740
|
biostudies-literature
Cite
Increased numbers of CD23(+) CD21(hi) Bin-like B cells in human reactive and rheumatoid arthritis lymph nodes.
Not available
S-EPMC4942352
|
biostudies-literature
Cite
Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN.
Not available
S-EPMC6642027
|
biostudies-literature
Cite
Single-cell resolution landscape of equine peripheral blood mononuclear cells reveals diverse cell types including T-bet
+
B cells.
Not available
S-EPMC7820527
|
biostudies-literature
Cite
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
Not available
S-EPMC4798896
|
biostudies-literature
Cite
Previous
page
1 / 29
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
29
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
